Brief: Medicenna Provides Positive Interim Update From Phase 2B Trial Of MDNA55 In Recurrent Glioblastoma

Medicenna Therapeutics

31/10/2018 11:43

Oct 31 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA PROVIDES POSITIVE INTERIM UPDATE FROM PHASE 2B
TRIAL
OF MDNA55 IN RECURRENT GLIOBLASTOMA
    * MEDICENNA - PROMISING INTERIM EFFICACY, SAFETY RESULTS
FROM
PATIENTS TREATED AT LOW DOSES IN ON-GOING PHASE 2B CLINICAL
TRIAL OF MDNA55
    * MEDICENNA - REVIEW OF SAFETY DATA TO DATE INCLUDING HIGH
DOSE
COHORTS SHOWED THAT SAFETY PROFILE OF MDNA55 WAS UNCHANGED FROM
PREVIOUS STUDIES

Source text for Eikon:  ID:nCNW485X3a 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))